ChromaDex

Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ChromaDex reports record revenue and eyes growth through partnerships

ChromaDex's strong revenue growth and positive EBITDA reflect operational improvements.
The company faces challenges in sales channels and marketing claims but sees growth opportunities.
Strategic focus on new partnerships, product development, and pharmaceutical initiatives for future growth.

ChromaDex reports robust Q1 performance, eyes innovation for growth

ChromaDex's Q1 2023 performance was strong, with notable growth in revenue and positive cash flows. The company faces challenges in recurring revenue conversion and aims for improved financial metrics. However, opportunities lie in innovation, R&D, and potential partnerships for future growth.

ChromaDex reports strong Q2 earnings and eyes market expansion

ChromaDex's Q2 performance reflects robust revenue growth, strong partnerships, and a commitment to scientific excellence, positioning the company for continued success.
While facing challenges such as customer retention and working capital management, ChromaDex remains focused on profitability and strategic investments for future growth.
Opportunities in expanding market share, leveraging key partnerships, and enhancing customer loyalty present avenues for sustained revenue growth and market leadership.
With a solid financial position and a balanced approach to growth, ChromaDex is poised to navigate challenges and capitalize on opportunities in the evolving market landscape.

ChromaDex reports robust Q3 results, eyes growth through strategic partnerships

ChromaDex's Q3 performance reflects revenue growth, profitability, and operational efficiency, supported by strong financials and strategic partnerships.
The company's focus on innovation, market expansion, and cost control measures positions it well for sustained growth and competitive advantage.
While facing challenges in a dynamic market environment, ChromaDex's opportunities lie in product innovation, market diversification, and strategic partnerships.
Overall, ChromaDex's strategic initiatives and financial strength indicate a positive outlook for future growth and market expansion.

ChromaDex reports robust earnings, eyes growth through partnerships and innovation

ChromaDex delivered strong financial performance in Q4 2023 and full year 2023, driven by revenue growth, partnerships, and product demand.
While facing challenges in meeting consumer demand and optimizing resource allocation, the company remains focused on responsible practices and future growth opportunities.
With a solid financial foundation, strategic partnerships, and a focus on innovation, ChromaDex is poised for continued growth and market leadership in the dietary supplement industry.

ChromaDex reports revenue growth and strategic partnerships for future expansion

ChromaDex's Q1 2024 performance reflects revenue growth, positive EBITDA, and strategic initiatives for future expansion.
The company's strengths lie in subscriber base building, successful product SKUs, and stable market presence in key segments.
While facing challenges such as increased expenses and short-term R&D investments, ChromaDex is well-positioned for growth.
Opportunities in new partnerships, product development, and market exploration offer avenues for revenue growth and enhanced customer value.

ChromaDex reports revenue growth and product innovation in Q2

ChromaDex's Q2 2024 performance showed revenue growth, positive EBITDA, and a strong cash position.
The company's strengths lie in its innovative NIAGEN product line and positive clinical study outcomes.
Challenges include market misinformation and the need to adjust outlook due to product delays.
Opportunities exist in addressing specific health conditions and leveraging marketing strategies for growth.

ChromaDex (CDXC) reports record Q3 results and eyes growth

ChromaDex (CDXC) delivers strong Q3 performance with record revenue and profitability, driven by e-commerce and product launches.
Despite challenges in outlook adjustment and pricing strategies, the company's financial discipline and market focus position it for growth.
Opportunities lie in expanding product reach, FDA approvals, and strategic marketing to capitalize on market potential.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ChromaDex Corporation's (CDXC) CEO Rob Fried on Q1 2019 Results - Earnings Call Transcript

ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will ChromaDex (CDXC) Report Negative Q1 Earnings? What You Should Know

News for ChromaDex Stock (CDXC)